1. Aging Population and Increasing Incidences of Diseases Characterized by OAB are Expected to Drive the Market
In 2017, approximately 950 million were aged over 60 years old and above, which amounts to 13% of the global population. The prevalence of urinary indications, such as incontinence, usually increases with age. In a population-based study conducted globally, the estimated prevalence of overactive bladder (OAB) in Europe and Canada was found to be 12.8% in women and 10.8% in men. OAB has a major negative impact on the quality of life and health in the elderly. The increasing burden of OAB, along with other urinary ailments, may boost the overactive bladder treatment market. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceutical companies, are also likely to drive the market.
2. North America – Expected to Lead the Market
North America is expected to lead the overactive bladder treatment market. This can be credited to its well-established healthcare industry. With reimbursement of overactive bladder treatment, growing prevalence of the disease with rising age, and the presence of major players, the market is expected to peak during the forecast period. Due to the increasing prevalence of bladder over-activity, geriatric population, healthcare expenditure, and awareness about overactive bladder treatments, the Asia-Pacific region is expected to register the highest CAGR during the forecast period.
3. Idiopathic Overactive Bladder Treatment to Have the Largest Share
Segmented by disease type, the idiopathic overactive bladder treatment accounted for a major share of the market, in 2017, which can be attributed to its high prevalence. Due to the bladder muscle weakness post pregnancy and menopause, women are more vulnerable to the condition. This is expected to encourage key companies to invest in this segment. Increasing competition among the market players may lead to a decrease in the overall cost of treatment, during the forecast period (2018-2023).
4. Leading Companies of the Market Studied
The report also examines the role of the leading players involved in the market studied. Some of the key players listed in the study are:
- Allergan PLC.
- Apotex Inc.
- Astellas Pharma Inc.
- Aurobindo Pharma Limited
- Cogentix Medical Inc.
- Endo International PLC
- Hisamitsu Pharmaceutical Co. Inc.
- Intas Pharmaceuticals Ltd
- Johnson & Johnson
- Macleods Pharmaceuticals Ltd
- Medtronic PLC
- Mylan NV
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
About Overactive Bladder Treatment Market
The Mordor Intelligence report predicts that the overactive bladder treatment market may register a CAGR of about 2.9% during the forecast period. North America currently dominates the market, due to the increasing awareness of overactive bladder treatment in this region.
Mordor Intelligence is a market intelligence and advisory firm operating in 14 industry segments, serving over 600 clients worldwide.